MDT

96.25

-0.26%↓

A

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

A

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

A

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

A

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

A

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

Search

Charles River Laboratories International Inc

Aperta

SettoreSettore sanitario

219.49 -0.01

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

214.89

Massimo

227.8

Metriche Chiave

By Trading Economics

Entrata

2.9M

56M

Vendite

-27M

1B

EPS

2.43

Margine di Profitto

5.529

Dipendenti

18,700

EBITDA

-23M

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

-6.22% downside

Dividendi

By Dow Jones

Utili prossimi

18 feb 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.5B

10B

Apertura precedente

219.5

Chiusura precedente

219.49

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 370 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 gen 2026, 23:54 UTC

Discorsi di Mercato

CBA Could Underperform Again in 2026 -- Market Talk

12 gen 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 gen 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise on Weaker Yen -- Market Talk

12 gen 2026, 23:43 UTC

Discorsi di Mercato

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 gen 2026, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 gen 2026, 21:56 UTC

Discorsi di Mercato

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

12 gen 2026, 21:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

12 gen 2026, 21:18 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 gen 2026, 21:18 UTC

Discorsi di Mercato

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 gen 2026, 20:54 UTC

Utili

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 gen 2026, 20:48 UTC

Discorsi di Mercato

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 gen 2026, 20:33 UTC

Discorsi di Mercato

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 gen 2026, 20:18 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 gen 2026, 20:18 UTC

Acquisizioni, Fusioni, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 gen 2026, 19:39 UTC

Discorsi di Mercato

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 gen 2026, 19:36 UTC

Discorsi di Mercato

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 gen 2026, 19:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

12 gen 2026, 19:33 UTC

Discorsi di Mercato

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 gen 2026, 19:24 UTC

Acquisizioni, Fusioni, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 gen 2026, 19:22 UTC

Acquisizioni, Fusioni, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 gen 2026, 18:21 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 gen 2026, 18:20 UTC

Acquisizioni, Fusioni, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 gen 2026, 18:19 UTC

Discorsi di Mercato

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 gen 2026, 18:16 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 gen 2026, 18:09 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

12 gen 2026, 18:09 UTC

Discorsi di Mercato

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 gen 2026, 18:01 UTC

Acquisizioni, Fusioni, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 gen 2026, 18:00 UTC

Discorsi di Mercato

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

-6.22% in calo

Previsioni per 12 mesi

Media 202.1 USD  -6.22%

Alto 225 USD

Basso 170 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

173 / 370 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat